Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Modin

Showing results (101-110 of 118) with videos related to

Pageof 12
Sort By:
The New England Journal of Medicine|September 1, 2025
High-Dose Influenza Vaccine to Reduce HospitalizationsJacobo Pardo-Seco, Carmen Rodríguez-Tenreiro-Sánchez, Iago Giné-Vázquez, et al.
Circulation|June 7, 2025
A Nationwide Factorial Randomized Trial of Electronic Nudges to Patients With Chronic Kidney Disease and Their General Practices for Increasing Guideline-Directed Medical Therapy: The NUDGE-CKD TrialKristoffer Grundtvig Skaarup, Niklas Dyrby Johansen, Lisbet Brandi, et al.
NEJM Evidence|October 28, 2025
Cardiac Effects of Dapagliflozin in People with Chronic Kidney DiseaseKatja Vu Bartholdy, Niklas Dyrby Johansen, Kristoffer Grundtvig Skaarup, et al.
Circulation|November 10, 2025
High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled AnalysisNiklas Dyrby Johansen, Daniel Modin, Jacobo Pardo-Seco, et al.
American Heart Journal|May 31, 2026
A Pragmatic Randomized Trial to Evaluate the Vaccine Effectiveness of Bivalent RSV prefusion F Vaccine for Preventing RSV Hospitalizations in Adults (DAN-RSV): Trial Design UpdateMats C Højbjerg Lassen, Sine H Christensen, Niklas D Johansen, et al.
Lancet (London, England)|October 20, 2025
Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysisNiklas Dyrby Johansen, Daniel Modin, Jacobo Pardo-Seco, et al.
European Heart Journal|August 30, 2025
Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trialManan Pareek, Mats C Højbjerg Lassen, Niklas Dyrby Johansen, et al.
European Journal of Preventive Cardiology|June 18, 2026
Effect of RSV Vaccine in Older Adults with Atrial Fibrillation: A Prespecified Analysis of the DAN-RSV TrialCaroline Espersen, Mats C H Lassen, Niklas Dyrby Johansen, et al.
The New England Journal of Medicine|September 1, 2025
RSV Prefusion F Vaccine for Prevention of Hospitalization in Older AdultsMats C Højbjerg Lassen, Niklas Dyrby Johansen, Sine H Christensen, et al.
JAMA|August 30, 2025
Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults: A Prespecified Analysis of the DAN-RSV TrialMats C Højbjerg Lassen, Niklas Dyrby Johansen, Sine H Christensen, et al.
Pageof 12

Showing results (101-110 of 118) with videos related to

Sort By:
Pageof 12
The New England Journal of Medicine|September 1, 2025
High-Dose Influenza Vaccine to Reduce HospitalizationsJacobo Pardo-Seco, Carmen Rodríguez-Tenreiro-Sánchez, Iago Giné-Vázquez, et al.
Circulation|June 7, 2025
A Nationwide Factorial Randomized Trial of Electronic Nudges to Patients With Chronic Kidney Disease and Their General Practices for Increasing Guideline-Directed Medical Therapy: The NUDGE-CKD TrialKristoffer Grundtvig Skaarup, Niklas Dyrby Johansen, Lisbet Brandi, et al.
NEJM Evidence|October 28, 2025
Cardiac Effects of Dapagliflozin in People with Chronic Kidney DiseaseKatja Vu Bartholdy, Niklas Dyrby Johansen, Kristoffer Grundtvig Skaarup, et al.
Circulation|November 10, 2025
High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled AnalysisNiklas Dyrby Johansen, Daniel Modin, Jacobo Pardo-Seco, et al.
American Heart Journal|May 31, 2026
A Pragmatic Randomized Trial to Evaluate the Vaccine Effectiveness of Bivalent RSV prefusion F Vaccine for Preventing RSV Hospitalizations in Adults (DAN-RSV): Trial Design UpdateMats C Højbjerg Lassen, Sine H Christensen, Niklas D Johansen, et al.
Lancet (London, England)|October 20, 2025
Effectiveness of high-dose influenza vaccine against hospitalisations in older adults (FLUNITY-HD): an individual-level pooled analysisNiklas Dyrby Johansen, Daniel Modin, Jacobo Pardo-Seco, et al.
European Heart Journal|August 30, 2025
Effectiveness of bivalent respiratory syncytial virus prefusion F protein-based vaccine in individuals with or without atherosclerotic cardiovascular disease: the DAN-RSV trialManan Pareek, Mats C Højbjerg Lassen, Niklas Dyrby Johansen, et al.
European Journal of Preventive Cardiology|June 18, 2026
Effect of RSV Vaccine in Older Adults with Atrial Fibrillation: A Prespecified Analysis of the DAN-RSV TrialCaroline Espersen, Mats C H Lassen, Niklas Dyrby Johansen, et al.
The New England Journal of Medicine|September 1, 2025
RSV Prefusion F Vaccine for Prevention of Hospitalization in Older AdultsMats C Højbjerg Lassen, Niklas Dyrby Johansen, Sine H Christensen, et al.
JAMA|August 30, 2025
Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults: A Prespecified Analysis of the DAN-RSV TrialMats C Højbjerg Lassen, Niklas Dyrby Johansen, Sine H Christensen, et al.
Pageof 12